ScreenerHero

ERNA Ernexa Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · ernexatx.com
2.490USD+4.18%Mkt Cap: 4.06M $P/E: —

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap4.06M USD
Enterprise Value-776.54K USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-14.08M USD
Revenue/Share—
Last Price2.490 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.26
PEG—
EV/EBITDA0.07
EV/Revenue—
P/S—
P/B0.91
EPS (TTM)-13.63
EPS (Forward)-9.60
52W Range
2.1351% of range71.50
52W High71.50 USD
52W Low2.135 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-586.59%
ROA-241.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.02M USD
CapEx (TTM)37.00K USD
FCF Margin—
FCF Yield-145.87%
Net Debt-4.68M USD
Net Debt/EBITDA0.40
Balance Sheet
Debt/Equity0.20
Current Ratio2.01
Quick Ratio1.74
Book Value/Sh2.73 USD
Cash/Share3.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateMay 4, 2026
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Upside (mean)+1104.8%
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.1.63M
Float1.22M
Insiders29.53%
Institutions2.18%
Short Interest
Short Ratio0.3d
Short % Float1.20%
Short % Out.0.88%
Shares Short14.36K
Short (prev mo.)24.66K
Technical
SMA 503.980 (-37.4%)
SMA 2009.826 (-74.7%)
Beta2.65
S&P 52W Chg15.84%
Avg Vol (30d)33.14K
Avg Vol (10d)101.00K
Technical Indicators
RSI (14)28.9
MACD-0.5059
MACD Signal-0.4112
MACD Hist.-0.0947
BB Upper4.655 USD
BB Middle3.413 USD
BB Lower2.171 USD
BB Width72.77%
ATR (14)0.4008 USD
Vol Ratio (20d)8.33x